

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**華潤醫藥集團有限公司**

**China Resources Pharmaceutical Group Limited**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3320)**

**INSIDE INFORMATION  
COMPLETION OF THE ISSUANCE OF THE SECOND  
TRANCHE OF ULTRA SHORT-TERM DEBENTURE 2019  
IN THE PRC**

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcements of China Resources Pharmaceutical Group Limited (the “**Company**”) dated 28 February 2019 and 11 June 2019 (the “**Announcements**”) in relation to, among others, acceptance of registration of debt of financing instruments by the National Association of Financial Market Institutional Investors, the proposed issuance of debt financing instruments (including ultra short-term debentures, short-term debentures, medium-term notes and perpetual notes) in the PRC and completion of the issuance of the first tranche of ultra short-term debentures 2019 in the PRC. Capitalised terms used herein shall have the same meanings as those defined in the Announcements unless stated otherwise herein.

The Board is pleased to announce that China Resources Pharmaceutical Holdings has completed the issuance of the second tranche of Ultra Short-Term Debentures 2019. The second tranche of Ultra Short-Term Debentures 2019 has been issued in a principal amount of RMB1.5 billion with a term of 90 days and a coupon rate of 2.70% per annum.

The proceeds raised from the issuance of the second tranche of Ultra Short-Term Debentures 2019 will mainly be used for the replenishment of daily working capital of China Resources Pharmaceutical Commercial Group Company Limited (華潤醫藥商業集團有限公司), an indirect wholly-owned subsidiary of CR Pharmaceutical Holdings.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board of Directors  
**China Resources Pharmaceutical Group Limited**  
**WANG Chuncheng**  
*Chairman*

Hong Kong, 29 August 2019

*As of the date of this announcement, executive Directors are Mr. WANG Chuncheng, Mr. LI Xiangming, Mr. QIU Huawei and Mdm. WENG Jingwen; the non-executive Directors are Mr. YU Zhongliang, Mdm. GUO Wei, Mr. WANG Shouye and Mr. LYU Ruizhi; and the independent non-executive Directors are Mdm. SHING Mo Han Yvonne, Mr. KWOK Kin Fun, Mr. FU Tingmei and Mr. ZHANG Kejian.*